ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $59.59 and traded as low as $55.06. ProShares Ultra Nasdaq Biotechnology shares last traded at $55.17, with a volume of 9,601 shares trading hands.
ProShares Ultra Nasdaq Biotechnology Trading Up 0.2 %
The business has a 50 day simple moving average of $53.32 and a two-hundred day simple moving average of $59.41.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently declared a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were paid a $0.3964 dividend. The ex-dividend date of this dividend was Monday, December 23rd. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock valued at $270,000 after buying an additional 1,266 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in ProShares Ultra Nasdaq Biotechnology during the fourth quarter worth $51,000. Finally, Jane Street Group LLC boosted its holdings in ProShares Ultra Nasdaq Biotechnology by 8.4% in the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after purchasing an additional 374 shares during the period.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
